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Objectives: Chloramphenicol is a broad-spectrum antimicrobial widely available in sub-Saharan Africa. With
susceptibility re-emerging among Enterobacteriaceae in Blantyre, Malawi, we designed and evaluated a new
high-resolution melt (HRM) RT-PCR assay, ChloS-HRM, to identify chloramphenicol-susceptible infections in a
hospital setting.
Methods: Seventy-two previously whole-genome sequenced isolates of Escherichia coli and Klebsiella pneumo-
niae from the Queen Elizabeth Central Hospital, Malawi, were subjected to determination of chloramphenicol
MICs. Primers were designed to detect 18 chloramphenicol resistance genes that produce seven distinct peaks
correlating with different gene groups (catA1, catA2, catA3, catB2, catB group 3, cmlA and floR) following HRM
analysis. ChloS-HRM results were compared with MIC and WGS results.
Results: ChloS-HRM correctly identified 15 of 17 phenotypically susceptible isolates and 54 of 55 resistant iso-
lates, giving an accuracy of 88% in identifying susceptibility and 98% in identifying resistance. WGS identified 16
of 17 susceptible and 54 of 55 resistant isolates, giving an accuracy of 94% in identifying susceptibility and 98%
in identifying resistance. The single false-susceptible result had no detectable gene by ChloS-HRM or WGS.
Compared with WGS, ChloS-HRM had 100% sensitivity and specificity for catA (catA1–3), cmlA and floR, and 96%
specificity for catB; sensitivity could not be estimated due to the lack of catB in the clinical sample collection. The
overall agreement between MIC and HRM was 96% and between MIC and WGS it was 97%.
Conclusions: ChloS-HRM could support antimicrobial stewardship in enabling de-escalation from third-
generation cephalosporins by identifying chloramphenicol-susceptible infections. This would be valuable in areas
with chloramphenicol-susceptible MDR and XDR Enterobacteriaceae.
Introduction
The greatest burden of antimicrobial resistance (AMR) is in the
developing world where severe bacterial infection is an important
cause of morbidity and mortality1 and third-generation cephalo-
sporins are frequently both first- and last-line antimicrobials.
Although AMR prevalence data from sub-Saharan Africa are lim-
ited, available data consistently reveal that AMR is increasing,
particularly in the Enterobacteriaceae,2 with resistance to third-
generation cephalosporins encountered in up to 46% of isolates de-
pending on the setting.3 Between 1996 and 2016 in Malawi 68.3%
of Gram-negative infections were resistant to first-line drugs
amoxicillin or penicillin, chloramphenicol and co-trimoxazole com-
pared with just 6.6% of Gram-positive infections.4
With the current paucity of new drugs in the pipeline,5 reimple-
menting older ‘forgotten’ drugs is a potential solution, particularly
in resource-limited settings.6 Many of these drugs, such as chlor-
amphenicol, were introduced in the 1940s–70s and increasing re-
sistance has led to their restriction or removal from clinical use.7 In
their absence susceptibility has returned, increasing their utility in
treating susceptible infections.8,9 This is particularly important with
the increasing prevalence of ESBLs and carbapenemases reducing
the effectiveness of first-line agents.
Chloramphenicol was discovered in 194710 and became widely
used due its broad activity against many Gram-positive and -nega-
tive species; however, by the 1960s it had largely been abandoned
in high-income countries due to its toxicity profile.11 Despite this it
VC The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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remains a key drug in low- and middle-income countries due to its
low price and ease of production.
Reports of returning chloramphenicol susceptibility are increas-
ing.9 Studies in Indian hospitals have found that 68% of MDR Gram-
negative bacteria12 and 62.5% colistin-resistant Gram-negative
bacteria13 were susceptible to chloramphenicol. In Malawi chloram-
phenicol was used in combination with benzylpenicillin as the first-
line therapy in the empirical management of suspected sepsis, until
2015.4 Irrespective of the national guidelines, ceftriaxone has been
widely used in Malawi since 2005, partly due to ease of administra-
tion (once daily) and partly because the most common cause of
bloodstream infection was MDR Salmonella enterica,14 reducing
chloramphenicol use. Susceptibility to chloramphenicol has been
gradually returning; resistance rates in 2016 were 61% in
Escherichia coli and 48% in Klebsiella pneumoniae compared with
80% of E. coli15 and 81% of K. pneumoniae in 2001.4 The regulated
reintroduction of chloramphenicol for the treatment of susceptible
isolates could reduce the duration of courses of third-generation
cephalosporins, protecting these vital agents.8
Chloramphenicol resistance is most commonly due to enzym-
atic inactivation by chloramphenicol acetyltransferases (CAT), of
which there are two structurally distinct types: CAT-A and CAT-B.16
There are at least 16 catA genes, with catA1–3 found in
Enterobacteriaceae,16–18 alongside catB2 and catB3 group 3
(catB3–6and catB8).16 Resistance also occurs due to efflux mecha-
nisms mediated by cml and floR genes.16 Additional chloram-
phenicol resistance genes found in Gram-positive species include
fexA and fexB from Staphylococcus, the ABC-F gene optrA from
Enterococcus spp.19 and Staphylococcus spp.,20 and the multire-
sistance genes cfr, cfr(B) and cfr(C), which have been sporadically
detected in Proteus spp. and E. coli.21
Typically, phenotypic testing requires an overnight culture step
to isolate the organism, followed by additional culture-based drug
susceptibility testing with results available within 48–72 h. This
delay results in the prolonged use of empirical broad-spectrum
antimicrobials and drives resistance. Molecular assays, however,
can be performed from the initial overnight culture, with a result
available within 2–3 h, including the DNA extraction process. We
report here the design of an RT-PCR assay to detect chlorampheni-
col susceptibility in E. coli and Klebsiella spp. employing high-
resolution melt (HRM) analysis, which enables a high degree of
multiplexing, without expensive fluorescent probes.22
Materials and methods
Ethics
The collection of the isolates during routine surveillance was approved by
the University of Malawi College of Medicine Research and Ethics
Committee (COMREC), Blantyre, under study number P.08/14/1614.
Bacterial isolates
Seventy-two previously whole-genome sequenced bacterial isolates,15 all
from separate patients, were collected in Queen Elizabeth Central Hospital,
Blantyre, Malawi between 1998 and 2016. The collection consisted of 39
E. coli and 33 K. pneumoniae, and included 61 isolated from blood culture,
10 from CSF and 1 from a rectal swab.
Isolates were transported to the Liverpool School of Tropical Medicine
(LSTM), Liverpool, UK on microbiological beads (Biobank) on dry ice where
they were stored at#80C.
Identifying resistance genes from WGS data
The sequencing of the isolates using the Illumina Hiseq 2000 platform
(Illumina, Inc., San Diego, CA, USA), de novo assembly and sequence anno-
tation was reported by Musicha et al.15
The final annotated sequences were screened for acquired AMR genes
using NCBI BLAST against a bespoke database of genes curated by the
Wellcome Trust Sanger Institute based on the ResFinder database. A cut-
off of .95% for nucleotide identity and .90% for coverage against the
database was used to confirm gene identity.
DNA extraction
Cultures were revived from microbiological beads (BioBank) using Mueller–
Hinton agar (Sigma) plates and incubated at 37C overnight. Single colonies
were selected and DNA was extracted using a DNeasy Blood and Tissue kit
(Qiagen, Germany) following the protocol for Gram-negative bacteria.
Chloramphenicol MICs
Chloramphenicol MIC assays were performed following EUCAST 2018
guidelines.23 Briefly, a single colony from each isolate was added to 5 mL of
Mueller–Hinton broth and incubated at 37C overnight. The culture was
diluted to 1%105 cfu/mL and added to a 96-well plate containing triplicates
of 512 to 0.2 mg/L chloramphenicol in Mueller–Hinton broth and incubated
at 37C overnight. A concentration of 8 mg/L was used as the breakpoint for
resistance as per the EUCAST guidelines.23
Primer design
Primers were designed for all the major chloramphenicol resistance genes
found in Enterobacteriaceae: catA1, catA2, catA3, catB2, catB3 group 3
(including catB3, catB4, catB5, catB6 and catB8), cmlA (cml, cmlA, cmlA1,
cmlA3, cmlA4, cmlA5, cmlA6 and cmlA7) and floR.16,24 Sequences for each
gene were downloaded from NCBI GenBank and aligned using ClustalX in
MEGA 7.0.14 to identify conserved sites.15 The 16S rRNA primers were
designed with a mismatch on the 30 end of the forward primer to any non-
Enterobacteriaceae species preventing amplification,25 and produced sep-
arate peaks for K. pneumoniae and E. coli. Primers were designed using
Primer3 (http://primer3.ut.ee/) to give each amplicon a distinct melting
temperature (Tm) for identification following HRM analysis. Amplicon Tm
was estimated using the nearest neighbour method on OligoCalc (http://bio
tools.nubic.northwestern.edu/OligoCalc.html). Primer sequences, concen-
trations and amplicon details are displayed in Table S1 (available as
Supplementary data at JACOnline).
ChloS-HRM assay
The ChloS-HRM assay was performed in a total volume of 12.5lL, consist-
ing of 6.25lL of 2% HRM Type-It mix (Qiagen), variable concentrations of
each primer (Table S1), molecular-grade water and 2.5lL of the DNA tem-
plate. All HRM development and evaluation runs were performed on a
Rotor-Gene Q 6000 (Qiagen, Germany) with the following conditions: Taq
activation at 95C for 5 min, then 30 cycles of 95C for 10 s, 62C for 30 s
and 72C for 20 s. The subsequent HRM step consisted of melting from 73C
to 89C, reading at every 0.1C step with a 2 s stabilization. Data analysis
was carried out using the Rotor-Gene Q software.
Isolates carrying chloramphenicol resistance genes according to WGS
data were used to confirm the Tm and location of the peak for each gene.
catA3 and catB were not available in the Malawian isolates and therefore
synthesized sequences of catA3 (NCBI reference sequence: NG_052661.1)
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and catB2 (NCBI reference sequence: NG_047602.1) (Eurofins) and a
K. pneumoniae isolate from the LSTM archive carrying the catB3 gene were
used as positive controls. Calling bins were set for each gene, including 16S
rRNA, and a positivity cut-off of 10% maximum peak fluorescence was set
at 0.5 dF/dT (Figure S1). Any isolate with a peak within a defined calling bin
over the positivity cut-off value was classified as positive for the corre-
sponding gene. Any isolate that generated no resistance peaks but pro-
duced a 16S rRNA peak was classified as susceptible to chloramphenicol.
Pilot study
The 72 bacterial isolates were tested with the ChloS-HRM assay using the
pre-defined calling bins and positivity cut-off value by an operator blinded
to the MIC and sequencing results. The ChloS-HRM results were compared
against the MIC results as a reference standard and the detection of specific
genes was compared with WGS data.
Hypothetical cohorts
To estimate the performance of ChloS-HRM we determined assay out-
comes with hypothetical cohorts of 1000 patients in areas with differing
levels of chloramphenicol resistance prevalence (90% to 10%). The nega-
tive predictive value (NPV), positive predictive value (PPV) and an estimation
of the number of cases where treatment could change were calculated.
Results
MICs
A total of 55 isolates, 26 E. coli and 29 K. pneumoniae, were classi-
fied as resistant, with an MIC range of 64–512 mg/L, and 17 iso-
lates, 13 E. coli and 4 K. pneumoniae, were classified as susceptible,
with an MIC range of 1–8 mg/L (Figure 1).
Comparison of chloramphenicol resistance gene
carriage by WGS and MIC
Of the 17 susceptible isolates, 1 contained a floR gene by WGS and
had an MIC of 8 mg/L giving WGS an accuracy of 94% (95% CI:
71.31%–99.85%) in detecting susceptibility. All other susceptible
isolates had no resistance genes by WGS. Of the 55 resistant iso-
lates, 50 had a single resistance gene by WGS; 49 contained catA
and 1 isolate contained floR. Four isolates had two resistance
genes (2% catA and cmlA, 1% catA and floR, and 1% cmlA and
floR), all of which had an MIC of 512 mg/L (Figure 1). A single isolate
with an MIC of 64 mg/L had no AMR gene by WGS, giving WGS an
accuracy of 98% (95% CI: 90.28%–99.95%) in identifying resistant
isolates.
Pilot study
The ChloS-HRM results were compared with MIC data to deter-
mine its accuracy in identifying susceptible isolates (Table 1).
The HRM assay correctly identified 15 of 17 chloramphenicol-
susceptible isolates, giving an accuracy of 88% to identify
susceptibility (95% CI: 63.56%–98.54%). Of the two isolates
falsely classified as resistant by ChloS-HRM, one had a peak for
catB group 3 and the other had a peak for floR; this isolate was
also positive for floR by WGS. A total of 54 of 55 MIC resistant
isolates were classified correctly by the HRM assay, giving an
accuracy of 98% (95% CI: 90.28%–99.95%) in identifying re-
sistant isolates. The single false-susceptible result had an MIC
of 64 mg/L but did not have any resistance genes detected by
HRM or WGS.
Compared with the WGS data the ChloS-HRM assay had 100%
sensitivity and 100% specificity for detecting catA (including
catA1–3), cmlA and floR (Table 2). The assay had a specificity of
96% for catB group 3; we were unable to estimate sensitivity due
to the lack of this gene in the sample collection. All four isolates
with two resistance genes by WGS were correctly identified by
ChloS-HRM.
The overall agreement between MIC testing and HRM was 96%
in classifying isolates, while the overall agreement between MIC
testing and WGS was 97%. See Table S2 for full MIC, WGS and
ChloS-HRM data for each isolate.
A 16S peak was detected in 65 of the 72 isolates (90%); all 7 iso-
lates without a 16S peak had at least one resistance marker peak,
indicating a successful RT-PCR. A total of 16 of 16 HRM susceptible
isolates produced a 16S peak and the correct species was identi-
fied in 64 of 64 isolates (100%).
Table 1. Accuracy of the ChloS-HRM assay compared with MIC results and the associated treatment outcomes for each isolate
True susceptible
(correctly de-escalated
to chloramphenicol)
True resistant
(correctly continue
b-lactam therapy)
False susceptible
(incorrect de-escalation:
potential treatment failure)
False resistant (incorrectly
continue b-lactam
therapy: overuse)
E. coli 12 25 1 1
K. pneumoniae 3 29 0 1
Total 15/17 (88%) 54/55 (98%) 1/55 (2%) 2/17 (12%)
No. of chloramphenicol resistance genes
M
IC
 (
m
g/
L)
0 1 2
1
2
4
8
16
32
64
128
256
512
EUCAST
breakpoint
Figure 1. MIC data for the 72 isolates showing the effect of chloram-
phenicol resistance gene carriage as characterized by WGS.
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Hypothetical cohorts
The hypothetical cohort indicated that as susceptibility prevalence
increases, so too does the PPV in identifying susceptibility, while
the number of false-susceptible cases decreases (Table 3). Thus,
the higher the prevalence of susceptibility, the more effective the
assay is. Once susceptibility drops ,30%, where the PPV and NPV
are both 95%, there are too many false-susceptible results for the
assay to be effective. The most recent data in Malawi from 2016
indicated a susceptibility prevalence of 39% in E. coli giving a PPV of
97% and an NPV of 93%, and a susceptibility prevalence of 52% in
K. pneumoniae giving a PPV of 98% and an NPV of 89%.4
Discussion
We have developed a highly multiplexed HRM RT-PCR assay cap-
able of detecting 18 different chloramphenicol resistance genes
within seven melt peaks, along with a bacterial 16S rRNA control
enabling discrimination of E. coli and K. pneumoniae. These are the
two most prevalent causes of Gram-negative bacteraemia,
excluding Salmonella spp., in Malawi, and the pathogens most
strongly associated with ESBL production. The assay was used to
detect chloramphenicol-susceptible isolates in Malawi, where
rapid de-escalation from broad-spectrum b-lactams such as cef-
triaxone could be possible.
The assay was 88% accurate in identifying phenotypically sus-
ceptible isolates and 98% accurate in identifying resistant isolates.
Accurately identifying resistant infections is vital; false-susceptible
results would lead to the incorrect use of chloramphenicol on a re-
sistant infection, likely leading to treatment failure. The lower ac-
curacy in detecting susceptible infections would have less impact
on treatment success, as a false-resistant result would lead to the
continuation of broad-spectrum empirical therapy.
Molecular testing of AMR genes has been shown to correlate
well with phenotypic resistance in Enterobacteriaceae,26,27 and
our comparison of WGS data with MIC testing showed a 97%
agreement. However, as PCR-based methods detect the presence,
but not expression level or copy number of a gene, the effect of
these changes of transcription levels is not reflected in the result.28
PCR methods also cannot distinguish silenced resistance genes, in
these cases predicting resistance in susceptible isolates. Silent re-
sistance genes are sometimes reactivated in response to antibiotic
pressure but often remain silent.29
All catA, cmlA and floR genes were correctly detected; however,
the degenerate catB group 3 primers produced 3 of 72 false-
positive results; two of these isolates contained other resistance
genes and so did not affect the overall result. Degenerate primers
enable the detection of multiple catB genes, maximizing
sensitivity, but can lead to a higher likelihood of non-specific bind-
ing.30 In the two isolates containing only the floR resistance gene,
one had an MIC of 64 mg/L and the other an MIC of 8 mg/L, making
it chloramphenicol susceptible. WGS analysis did not reveal any
SNPs in the gene from this isolate15; however, the floR gene has
previously been shown to confer variable resistance.31,32
All chloramphenicol resistance genes reported in the
Enterobacteriaceae were included in the assay, with some rarely
encountered exceptions.16,24 All genes identified in Malawi during
a previous project sequencing resistant invasive isolates were
included.15 The MDR gene cfr, found predominantly in Gram-
positive species, but also rarely reported in E. coli and Proteus,21
was excluded. Data on cfr in E. coli and K. pneumoniae are still very
scarce, particularly in sub-Saharan Africa.
The Enterobacteriaceae 16S internal control was successfully
amplified in 65 of 72 (90%) isolates. 16S primer concentrations
were deliberately lower than the other sets to prevent amplifica-
tion of the 16S gene occurring to the detriment of more important
resistance genes. All seven of the samples where the peak was ab-
sent contained at least one resistance peak.
Estimation of test outcomes on hypothetical cohorts illustrated
that as the prevalence of susceptibility increases, the number of false-
susceptible infections decreases, thus increasing the PPV and enhanc-
ing the potential for de-escalation of therapy. Chloramphenicol resist-
ance in the Enterobacteriaceae ranges between 31% and 94.2%
depending on the setting;3,12 therefore, the implementation of this
test must be considered alongside local resistance rates.
Recent WGS studies in Malawi found that 56 of 134 (41.8%) of
ESBL-containing E. coli15 and 41 of 262 (15.6%) ESBL-containing
K. pneumoniae39 were chloramphenicol susceptible, highlighting
that the ChloS-HRM assay would prove effective in de-escalating
to a more effective treatment option, particularly in E. coli.
Furthermore, reports of chloramphenicol-susceptible S. enterica
are also increasing.33–37 As resistance is mediated by the genes
that the ChloS-HRM assay identifies,16 it could potentially identify
susceptibility in this species. The identification of chloramphenicol
susceptibility could also provide a welcome addition to the dimin-
ishing options available for treating for MDR and XDR
Enterobacteriaceae.
Affordability of antibiotics is critical for low- and middle-income
countries, particularly in countries such as Malawi where the public
healthcare system provides treatment for free.38 Chloramphenicol
is highly affordable in comparison with carbapenems, the next line
of antimicrobial chemotherapy, and increased use would likely be
cost saving.
The ChloS-HRM assay enables the sensitive detection of
chloramphenicol-susceptible E. coli and K. pneumoniae, allowing
Table 2. Sensitivity and specificity of the ChloS-HRM assay in detecting resistance markers compared with WGS
HRM versus WGS
catA catB cmlA floR
Sensitivity (%) 100 (52/52 TP) – 100 (3/3 TP) 100 (4/4 TP)
Specificity (%) 100 (20/20 TN) 96 (70/72 TN) 100 (69/69 TN) 100 (68/68 TN)
TP, true positive; TN, true negative.
Williams et al.
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the de-escalation to chloramphenicol and enhancing antimicro-
bial stewardship. De-escalation to chloramphenicol would also
prevent escalation to carbapenems and so would also be protect-
ive of this class of drugs as well as cephalosporins. The test would
be a powerful tool for molecular epidemiology and surveillance
studies on chloramphenicol resistance, where WGS is not feasible.
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